Galaxolide-13C-d2
CAS: 1222-05-5
Ref. 4Z-G-159002
| 10mg | To inquire | ||
| 25mg | To inquire | ||
| 50mg | To inquire | ||
| 100mg | To inquire |
Estimated delivery in United States, on Monday 13 Jan 2025
Product Information
Name:
Galaxolide-13C-d2
Synonyms:
- 1,3,4,6,7,8-HEXAHYDRO-4,6,6,7,8,8- HEXAMETHYL CYCLOPENTA-γ-2-BENZOPYRAN
- 1,3,4,6,7,8-Hexahidro-4,6,6,7,8,8-Hexametilindeno[5,6-C]Pirano
- 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-Hexamethylindeno(5,6-C)Pyr
- 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-Hexamethylindeno[5,6-C]Pyranne
- 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethyl-cyclopenta-gamma-2-benzopyran
- 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclo-penta[g]-2-benzo pyrane
- 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[g]-2-benzopyran
- 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylcyclopenta[g]-2-benzopyrane
- 1,3,4,6,7,8-Hexahydro-4,6,6,7,8,8-hexamethylindeno[5,6-c]pyrane
- 1,3,4,6,7,8-Hexahydro-4,6,6,8,8,8-hexamethylcyclopenta-2-benzopyran
- See more synonyms
- 1-[2-(Dimethylamino)-1-(4-Methoxyphenyl)Ethyl]Cyclohexanol Hydrochloride (1:1)
- 4,6,6,7,8,8-Hexamethyl-1,3,4,6,7,8-Hexahydrocyclopenta[G]Isochromene
- Abbalide
- Cimalide 50
- Cyclopenta[g]-2-benzopyran, 1,3,4,6,7,8-hexahydro-4,6,6,7,8,8-hexamethyl-
- Galaxolide
- Galaxolide 50
- Galaxolide 50BB
- Galaxolide 50IPM
- Galaxolide Abbalide
- Galaxolide White
- Hhcb
- Pearlide
- Venlafaxine
Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
TLC
Long term storage:
Notes:
Chemical properties
Molecular weight:
261.41
Formula:
CC17H24D2O
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:
Technical inquiry about: 4Z-G-159002 Galaxolide-13C-d2
Please use instead the cart to request a quotation or an order
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
